Dr. Sanjeeva Srivastava is Associate Professor and group leader of proteomics laboratory at Indian Institute of Technology, Bombay. He obtained his Ph.D from the University of Alberta and post-doc from the Harvard Medical School in the area of proteomics, stress physiology and has specialized expertise in applications of data enabled sciences in global health, developing country and resource limited settings. Current research in this group centers on biomarker and drug target discovery and deciphering the protein interaction networks in complex human diseases (gliomas) and infectious diseases (malaria) using high throughput proteomics, protein microarrays and mass spectrometry. Dr. Srivastava is an active contributor to global proteomics science and innovation. He serves on the Council of Human Proteome Organization (HUPO) and Executive Committee of Proteomics Society, India (PSI). He had organized two successful conferences – PSI-2014 and Targeted Proteomics International Symposium in 2015. He has published three special issues as editor, “Proteomics in India” for Journal of Proteomics; “Proteomics Research in India” for Nature India and “Protein Arrays” for Proteomics. Having extensive teaching experience at IITB and experience of conducting proteomics courses at CSHL provided him with the background to increase proteomics education for the global community. One of his special contributions has been the development of e-learning resources (MOOC, Virtual Proteomics Laboratory). He continues to develop proteomics & omics science and innovation together with and for the next generation of keen students, researchers and the research and education commons in Asia and global OMICS community.


Glioma brain tumors arise from glial cells. Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors. We have performed a comprehensive iTRAQ-based quantitative tissue proteomic analysis of gliomas and compared it with different controls, including other cancer samples as disease control to identify differentially expressed proteins in different groups of brain tumors. The iTRAQ-labeled peptides were fractionated using off-gel fractionation followed by LC-MS/MS analysis. Various metabolic pathways including fructose & mannose metabolism, spliceosome and aminoacid metabolism were found to be altered in GBM, medulloblastoma and meningiomas respectively. Proteins like CRYAB, GFAP, BASP1 and SNCA were found to be significantly altered in gliomas, where as VIM, RABP1, ANXA2 and SBP1 showed differential expression in meningiomas.  Protein biomarkers identified from discovery-phase were further validated using MRM-based quantitative approach. Targeted proteomics data was analyzed using Skyline and for each protein a minimum of 3 peptides with at least 3 corresponding transitions were used for quantification. The in-solution digested peptides from the tissue lysates were run on triple quadrupole mass spectrometry. This comprehensive mass spectrometry based quantitative and targeted proteomic profiling of brain tumors identified few potential markers and provided insights into tumor pathophsyiology.